• 1. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy
  Michael Kappl,Paul M. Young,Daniela Traini,Sanyog Jain RSC Adv., 2016,6, 25789-25798

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzonitriles
• Other Chemical Reagents Derivatization Reagents
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Introduction to 3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (CAS No. 1035235-29-0)

3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its Chemical Abstracts Service (CAS) number 1035235-29-0, is a key intermediate in the synthesis of various biologically active molecules. Its unique structural features, particularly the presence of a fluoro-substituted benzonitrile core and a tetramethyltetrahydrodioxaborolane boronic ester moiety, make it a valuable building block for drug discovery initiatives.

The fluoro-substituent in the benzene ring plays a crucial role in modulating the pharmacokinetic and pharmacodynamic properties of drug candidates. Fluorine atoms are known to influence metabolic stability, binding affinity, and overall bioavailability of therapeutic agents. In particular, C-F bonds are characterized by their high bond dissociation energy, which contributes to increased chemical stability and resistance to degradation. This property is particularly advantageous in the development of long-acting drugs that require sustained efficacy.

The tetramethyltetrahydrodioxaborolane group attached to the benzonitrile scaffold serves as an effective boronic ester moiety. Boronic acids and their esters are widely employed in Suzuki-Miyaura cross-coupling reactions, a cornerstone of modern organic synthesis. This reaction allows for the formation of carbon-carbon bonds between aryl or vinyl halides and boronic acids/sters, enabling the construction of complex molecular architectures with high precision. The use of this boronic ester derivative facilitates the introduction of diverse functional groups into drug-like molecules, enhancing their potential as therapeutic agents.

In recent years, there has been a surge in research focused on developing novel pharmaceuticals with enhanced efficacy and reduced side effects. The benzonitrile core is a common structural motif in many approved drugs due to its ability to interact favorably with biological targets such as enzymes and receptors. The incorporation of a fluoro-substituent further refines these interactions by improving lipophilicity and metabolic resistance. This combination makes 3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile an attractive candidate for further exploration in medicinal chemistry.

One of the most compelling applications of this compound lies in its utility as a precursor for the synthesis of small-molecule inhibitors targeting various disease pathways. For instance, researchers have leveraged similar boronic ester-containing intermediates to develop kinase inhibitors that play a critical role in treating cancers and inflammatory diseases. The fluoro-substituted benzonitrile moiety can be further modified through cross-coupling reactions to introduce additional functional groups that enhance binding affinity to specific biological targets. This modular approach allows for rapid iteration and optimization of drug candidates.

The synthesis of 3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile involves multi-step organic transformations that highlight the ingenuity of modern synthetic chemistry. The process typically begins with the preparation of the tetramethyltetrahydrodioxaborolane boronic ester via lithiation-borylation sequences followed by functionalization at the para-position relative to the nitrile group. Advanced catalytic systems have been employed to ensure high yields and selectivity throughout these reactions. Such methodologies underscore the importance of well-designed synthetic routes in enabling access to complex molecular architectures.

Recent advancements in computational chemistry have further accelerated the development pipeline for compounds like 3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile. Molecular modeling techniques allow researchers to predict how modifications to the structure will impact biological activity with remarkable accuracy. This predictive power has enabled virtual screening campaigns that identify promising lead compounds before they are synthesized in the laboratory. Such innovations are reshaping drug discovery by reducing time-to-market while maintaining high standards of efficacy and safety.

The pharmaceutical industry continues to invest heavily in developing next-generation therapeutics based on fluorinated heterocycles such as benzonitriles. These compounds exhibit unique physicochemical properties that make them ideal candidates for treating conditions ranging from oncology to neurodegenerative disorders. The versatility of 3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile lies in its ability to serve as a scaffold for generating libraries of derivatives with tailored biological profiles through combinatorial chemistry approaches.

In conclusion,3-Fluoro-4-(4,,4,,5,,5-tetramethyl-*1,*3,*2*-dioxaborolan-*2*-yl)benzonitrile (CAS No. 1035235*-*29*-*0*) represents an important tool for synthetic chemists engaged in drug development programs worldwide.* Its unique structural features,* including* a *fluoro-substituted benzonitrile* core* and* a *tetramethyltetrahydrodioxaborolane* boronic ester,* endow it with significant potential* for generating novel therapeutics.* As research progresses,* this compound* will likely find applications* across multiple therapeutic areas*, reinforcing its value* as both* an academic research tool* and* an industrial intermediate.* The ongoing development* of innovative synthetic methodologies* ensures that access* to such specialized reagents will remain robust,* supporting future breakthroughs* in medicinal chemistry.*

• 935685-88-4(3-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-benzonitrile)
• 1150271-75-2(2-Fluoro-4,5-dimethylphenylboronic Acid Pinacol Ester)
• 1218791-15-1(3-Cyano-2-fluorophenylboronic acid, pinacol ester)
• 1314141-37-1([3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol)
• 461451-63-8(5-fluoro-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile)
• 863868-41-1(Benzonitrile,4-fluoro-2,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-)
• 863868-29-5(4-Fluoro-3-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)Benzonitrile)
• 863868-42-2(Benzonitrile,4-fluoro-3,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-)
• 624741-47-5(3-Fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile)
• 1192023-08-7(4-Cyano-2-fluoro-5-methylphenylboronic acid, pinacol ester)